Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLYCO: AVD-104 in Diabetic Macular Edema
NCT06181227Phase 2Terminated
- Sponsor
- Aviceda Therapeutics
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avd-104 in diabetic macular edema (DME) (2 arms), sponsored by Aviceda Therapeutics. Primary endpoint: Incidence of Serious Adverse Events at 3 months. Started Nov 2023; status: terminated.
02
Drugs
avd-104
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06181227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181227.